JPWO2023105479A5 - - Google Patents
Info
- Publication number
- JPWO2023105479A5 JPWO2023105479A5 JP2024534144A JP2024534144A JPWO2023105479A5 JP WO2023105479 A5 JPWO2023105479 A5 JP WO2023105479A5 JP 2024534144 A JP2024534144 A JP 2024534144A JP 2024534144 A JP2024534144 A JP 2024534144A JP WO2023105479 A5 JPWO2023105479 A5 JP WO2023105479A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287557P | 2021-12-09 | 2021-12-09 | |
| US63/287,557 | 2021-12-09 | ||
| US202163290765P | 2021-12-17 | 2021-12-17 | |
| US63/290,765 | 2021-12-17 | ||
| PCT/IB2022/061991 WO2023105479A1 (en) | 2021-12-09 | 2022-12-09 | Use of amivantamab to treat colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025500784A JP2025500784A (ja) | 2025-01-15 |
| JPWO2023105479A5 true JPWO2023105479A5 (https=) | 2025-12-12 |
| JP2025500784A5 JP2025500784A5 (https=) | 2025-12-12 |
Family
ID=84537874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534144A Pending JP2025500784A (ja) | 2021-12-09 | 2022-12-09 | 結腸直腸癌を治療するためのアミバンタマブの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230183360A1 (https=) |
| EP (1) | EP4444426A1 (https=) |
| JP (1) | JP2025500784A (https=) |
| KR (1) | KR20240112963A (https=) |
| AU (1) | AU2022407875A1 (https=) |
| CA (1) | CA3241933A1 (https=) |
| IL (1) | IL313410A (https=) |
| MX (1) | MX2024007066A (https=) |
| WO (1) | WO2023105479A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202547867A (zh) * | 2024-01-16 | 2025-12-16 | 美商健生生物科技公司 | 使用阿米維單抗治療結腸直腸癌 |
| WO2026022733A1 (en) * | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
| WO2026022739A1 (en) * | 2024-07-23 | 2026-01-29 | Janssen Biotech, Inc. | Combination therapies for the treatment of colorectal cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| SG11202108311RA (en) * | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| PH12022552076A1 (en) * | 2020-02-12 | 2023-11-29 | Janssen Biotech Inc | TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS |
-
2022
- 2022-12-08 US US18/077,318 patent/US20230183360A1/en not_active Abandoned
- 2022-12-09 IL IL313410A patent/IL313410A/en unknown
- 2022-12-09 MX MX2024007066A patent/MX2024007066A/es unknown
- 2022-12-09 WO PCT/IB2022/061991 patent/WO2023105479A1/en not_active Ceased
- 2022-12-09 CA CA3241933A patent/CA3241933A1/en active Pending
- 2022-12-09 KR KR1020247022472A patent/KR20240112963A/ko active Pending
- 2022-12-09 AU AU2022407875A patent/AU2022407875A1/en active Pending
- 2022-12-09 JP JP2024534144A patent/JP2025500784A/ja active Pending
- 2022-12-09 EP EP22826446.1A patent/EP4444426A1/en active Pending
-
2025
- 2025-01-17 US US19/028,911 patent/US20250257139A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020099324A5 (https=) | ||
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| JP2020509027A5 (https=) | ||
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| JP2020508317A5 (https=) | ||
| JP2023502585A (ja) | 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害 | |
| CA2937024A1 (en) | Anti-met in combination with anti-vegfr2 antibodies therapy for cancer | |
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| CN114340679A (zh) | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 | |
| EP4464337A1 (en) | Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents | |
| TW202224683A (zh) | 用於治療肺癌之包含ｋｒａｓｇ１２ｃ抑制劑及ｐｄ—ｌ１結合拮抗劑的方法及組成物 | |
| JPWO2019246356A5 (https=) | ||
| CN112007162A (zh) | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 | |
| KR20240046526A (ko) | 소세포폐암 치료용 약학적 조성물 | |
| CN111148534A (zh) | 抗igf和抗pd-1抗癌组合疗法 | |
| JPWO2023105479A5 (https=) | ||
| JP2017515843A5 (https=) | ||
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| CN118697865A (zh) | 治疗淋巴瘤的药物组合 | |
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| JPWO2022043895A5 (https=) | ||
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| CN106470698A (zh) | 组合疗法 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| WO2025244529A1 (en) | Dosing regimen of an egfr binding and/or complement activating antibody |